Celldex Therapeutics (CLDX) vs Myriad Genetics (MYGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Celldex Therapeutics (CLDX) has outperformed Myriad Genetics (MYGN) over the past year, gaining 16.1% versus a loss of 43.2%. Over five years, CLDX leads with a -34.1% price change compared with -86.5% for MYGN. Celldex Therapeutics is the larger company by market cap ($2.30 billion vs $401.7 million), about 5.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDX | MYGN |
|---|---|---|
| Share price | $29.30 | $4.20 |
| Market cap | $2.30B | $401.73M |
| 1-day change | -3.71% | -1.87% |
| YTD return | +12.04% | -30.41% |
| 1-year return | +16.06% | -43.16% |
| 5-year return | -34.11% | -86.52% |
| EPS (TTM) | $-4.35 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54M | — |
| Revenue growth (YoY) | -77.99% | — |
| Net income (latest FY) | $-258.76M | — |
| Gross margin | 87.06% | — |
| Operating margin | -18599.81% | — |
| Net margin | -16748.03% | — |
| 52-week high | $45.14 | $8.59 |
| 52-week low | $22.10 | $2.74 |
| Distance from 52-week high | -35.09% | -51.11% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +115.26% | -6.90% |
| Average volume | 1.27M | 2.02M |
| Shares outstanding | 78.53M | 95.65M |
| Employees | 198 | 2,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Celldex Therapeutics is about 5.7 times larger than Myriad Genetics by market value ($2.30B vs $401.73M).
- CLDX has outperformed MYGN by 59.2 percentage points over the past year.
About Celldex Therapeutics
CLDX stock →Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 198 employees
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
CLDX vs MYGN FAQ
Which is bigger, Celldex Therapeutics or Myriad Genetics?
Celldex Therapeutics (CLDX) is larger, with a market capitalization of $2.30B compared with $401.73M for Myriad Genetics (MYGN).
Which stock has performed better over the past year, CLDX or MYGN?
CLDX returned +16.06% over the past 12 months, compared with -43.16% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Are Celldex Therapeutics and Myriad Genetics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.